Long-Term Outcomes with Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients

• DOI: 10.31557/apjcp.2023.24.5.1513
• Publication Date: 2023-05-29T16:49:12Z
• Authors: Saikhuan Towachir...; Teerachat Punnachet; Nonthakorn Hantrakun; Pokpong Piriyakhu...; Thanawat Rattanat...; Sasinee Hantrakool; Chatree Chai-Adis...; Ekarat Rattaritta...; Lalita Norasetthada; Adisak Tantiworawit
• Keywords: Adult; Male; Dasatinib; Tyrosine Kinase Inhibitors; HER2 Signaling in Breast Cancer Treatment; Efficacy and Resistance in CML Treatment; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Health Sciences; Genetics; Humans; Tyrosine-kinase inhibitor; Protein Kinase Inhibitors; Internal medicine; Retrospective Studies; Cancer; Hematology; Middle Aged; Nilotinib; 3. Good health; Treatment Outcome; Myeloid leukemia; Oncology; Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia; FOS: Biological sciences; Imatinib; Imatinib Mesylate; Medicine; Female; Research Article

Objective: Tyrosine kinase inhibitor (TKI) is the standard treatment for chronic myeloid leukemia (CML). In national list of essential medicines in Thailand, first, second, and third-line treatments are imatinib, nilotinib, dasatinib, sequentially, different from European Leukemia Net guidelines. This study aimed to evaluate outcomes CML patients who received sequential with TKI. Methods: enrolled diagnosed between 2008 2020 at Chiang Mai University Hospital Medical records were reviewed demographic data, risk score, response, event-free survival (EFS), overall (OS). Result: One hundred fifty included study, 68 (45.3%) female. The mean age 45.9 ± 15.8 years. Most (88.6%) had good ECOG status (0-1). diagnosis was phase 136 (90.6%). EUTOS long-term (ELTS) score revealed a high 36.7%. At median follow-up 8.3 years, 88.6% complete cytogenetic response (CCyR), whereas 58.0% major molecular (MMR). 10-year OS EFS 81.33% 79.33%, respectively. factors associated poor ELTS (P = 0.01), performance < 0.001), not achieved MMR within 15 months 0.014), CCyR 12 0.001). Conclusion: response. Factors predicting status, early achieving CCyR.